Lymphoma is cancer caused in lymphocytes, i.e. white blood cells. It is of two types – Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma. Hodgkin’s Lymphoma can be characterized into two categories – classic and nodular lymphocyte-predominant. Some of the symptoms of Hodgkin’s Lymphoma are fever, sudden weight loss, and swollen lymph nodes. Hodgkin’s Lymphoma is mostly treated with chemotherapy alone or with the combination of radiotherapy.
For More Information, Request sample copy of Business Report: https://www.coherentmarketinsights.com/insight/request-sample/2658
Global Hodgkin’s Lymphoma Treatment Market Drivers
Increasing approvals of the drugs by regulatory bodies for the treatment of Hodgkin’s lymphoma is projected to drive the global Hodgkin’s lymphoma market growth. In 2018, Seattle Genetics, Inc. received the Health Canada approval for its supplemental New Drug Submission that expands the use of Adcetris (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine, and dacarbazine) chemotherapy in patients with previously untreated Stage IV Hodgkin lymphoma (HL). Adcetris is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Furthermore, major players are constantly trying to expand the indications of their already approved drug. For instance, in March 2017, Merck & Co. Inc. received approval by the U.S. Food & Drug Administration (FDA) of the drug, Keytruda for the treatment of classical Hodgkin’s lymphoma. It is approved on the basis of effectiveness and is supposed to be administered intravenously into patients. It was originally approved in 2014. Such frequent approvals of drugs by regulatory bodies are expected to impact positively on the global Hodgkin’s lymphoma treatment market growth.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2658
Global Hodgkin’s Lymphoma Treatment Market Regional Analysis
North America is projected to hold a dominant position in the global Hodgkin’s lymphoma market over the forecast period. Rising research and development activities by the government and other organizations are expected to drive North America Hodgkin’s lymphoma treatment market growth. For instance, in December 2016, Ohio State University Comprehensive Cancer Center and National Cancer Institute (NCI) commenced a U.S. FDA clinical trial of Ibrutinib in combination with Nivolumab, in the patients suffering from classical Hodgkin’s Lymphoma, in the U.S to study its efficacy. Ibritunib may block cancer cell growth by blocking the enzymes responsible for growth and Nivolumab may block cancer cells by targeting different cells. Currently, it’s in the second phase of clinical trials. The study involves 17 participants and is estimated to be completed by 2020.
Furthermore, various organizations are also involved in research and development activities for the development of new drugs and gaining the U.S. FDA approval of novel Hodgkin’s lymphoma treatment drug in the U.S.
For instance, in September 2017, Chinese PLA General Hospital, a Chinese government organization, commenced its clinical trial of Decitabine in combination with SHR – 1210. It is being used for the treatment of Hodgkin’s lymphoma. SHR – 1210 is a monoclonal antibody, while Decitabine is an investigational drug, which is capable of boosting antigen expression. The clinical study is for analyzing the safety and efficacy of the drugs. Currently, it is in the second phase of clinical trials.
Global Hodgkin’s Lymphoma Treatment Market Restraints
Side effects associated with drugs used for the treatment of Hodgkin’s lymphoma are projected to adversely affect the adoption of these drugs, thereby hindering the global Hodgkin’s lymphoma treatment market growth. For instance, according to the American Cancer Society, drugs used for treating Hodgkin’s lymphoma such as doxorubicin and bleomycin can damage the heart and lungs respectively.
Global Hodgkin’s Lymphoma Treatment Market Key Players
Some of the major players operating in the global Hodgkin’s lymphoma treatment market include Emcure Pharmaceuticals Pvt. Ltd., Aspen Global Inc., Pfizer Inc., Ono Pharmaceuticals Co. Ltd., Corden Pharma Latina SPA, Horizon Pharma USA Inc., Cipla Ltd., Lediant Biosciences Inc., Janssen Research and Development LLC, and Merck & Co., Inc.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/hodgkins-lymphoma-treatment-market-2658
Global Hodgkin’s Lymphoma Treatment Market Taxonomy
The global Hodgkin’s lymphoma treatment market is segmented on the basis of treatment type, route of administration, distribution channel, and regions.
By Treatment Type
- Monoclonal Antibody
- Brentuximab Vedotin
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Table of Content
Global Hodgkin’s Lymphoma Treatment Market Research Report
Section 1: Global Hodgkin’s Lymphoma Treatment Industry Overview
Section 2: Global Economic Impact on Hodgkin’s Lymphoma Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Hodgkin’s Lymphoma Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Hodgkin’s Lymphoma Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027